older adults

EU health officials are recommending that people aged 35 and older undergo regular cardiovascular check-ups to catch heart disease earlier. The advice, reported by Medical Xpress, marks a shift toward preventive screening across member states. The recommendation is drawing attention as heart disease remains a leading cause of death in Europe and early detection can significantly reduce serious outcomes.

A new report finds that roughly one in nine older adults who use cannabis may meet the criteria for cannabis use disorder. The finding highlights growing concerns as cannabis use rises among older populations, raising questions about screening, education and support for this age group.

A new report finds that more than one in five older Americans take combinations of medications that could cause major drug interactions, with antidepressants topping the list of drugs involved. The findings raise concerns about polypharmacy among seniors, many of whom take multiple prescriptions for chronic conditions, and highlight the need for better medication review by doctors and pharmacists.

New research suggests glucosamine, a widely used joint supplement taken by millions for arthritis and cartilage health, may be associated with faster progression of Alzheimer's disease. The finding is striking because the over-the-counter remedy has long been considered safe, and it raises fresh questions about supplement safety in older adults. Coverage is drawing attention from patients and clinicians alike.

New Jersey education outlet NJ Spotlight News has published a Q&A examining whether older students and adults who previously dropped out of college could help reverse declining higher-education enrollment. The piece explores how re-engaging these groups might offset shortfalls as fewer traditional-age students enter colleges and universities, a challenge facing institutions across the United States.

Researchers suggest participants' age could account for why psychedelic studies produce differing conclusions about safety and effectiveness. Older adults may respond differently to substances like psilocybin or MDMA, meaning trials skewed toward younger or older volunteers could reach inconsistent findings. The claim highlights a gap in how psychedelic research is designed and interpreted.